MIRM Quote, Financials, Valuation and Earnings

BridgeBio Pharma, Inc. has a net margin of -3.85% compared to Mirum Pharmaceuticals, Inc.'s net margin of -126.24%. Mirum Pharmaceuticals, Inc.'s return on equity of -8.84% beat BridgeBio Pharma, Inc.'s return on equity of --.

Mirum Pharmaceuticals, Inc. has a consensus price target of $122.36, signalling upside risk potential of 32.59%. On the other hand BridgeBio Pharma, Inc. has an analysts' consensus of $100.05 which suggests that it could grow by 50.49%. Given that BridgeBio Pharma, Inc. has higher upside potential than Mirum Pharmaceuticals, Inc., analysts believe BridgeBio Pharma, Inc. is more attractive than Mirum Pharmaceuticals, Inc..

Mirum Pharmaceuticals, Inc. has a beta of 0.492, which suggesting that the stock is 50.821% less volatile than S&P 500. In comparison BridgeBio Pharma, Inc. has a beta of 1.128, suggesting its more volatile than the S&P 500 by 12.752%.

Mirum Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BridgeBio Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mirum Pharmaceuticals, Inc. pays -- of its earnings as a dividend. BridgeBio Pharma, Inc. pays out -- of its earnings as a dividend.

Mirum Pharmaceuticals, Inc. quarterly revenues are $148.9M, which are smaller than BridgeBio Pharma, Inc. quarterly revenues of $154.2M. Mirum Pharmaceuticals, Inc.'s net income of -$5.7M is higher than BridgeBio Pharma, Inc.'s net income of -$194.6M. Notably, Mirum Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while BridgeBio Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mirum Pharmaceuticals, Inc. is 9.17x versus 25.36x for BridgeBio Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

CorMedix, Inc. has a net margin of -3.85% compared to Mirum Pharmaceuticals, Inc.'s net margin of 49.9%. Mirum Pharmaceuticals, Inc.'s return on equity of -8.84% beat CorMedix, Inc.'s return on equity of 95.25%.

Mirum Pharmaceuticals, Inc. has a consensus price target of $122.36, signalling upside risk potential of 32.59%. On the other hand CorMedix, Inc. has an analysts' consensus of $14.86 which suggests that it could grow by 108.38%. Given that CorMedix, Inc. has higher upside potential than Mirum Pharmaceuticals, Inc., analysts believe CorMedix, Inc. is more attractive than Mirum Pharmaceuticals, Inc..

Mirum Pharmaceuticals, Inc. has a beta of 0.492, which suggesting that the stock is 50.821% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.388, suggesting its more volatile than the S&P 500 by 38.76%.

Mirum Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mirum Pharmaceuticals, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.

Mirum Pharmaceuticals, Inc. quarterly revenues are $148.9M, which are larger than CorMedix, Inc. quarterly revenues of $104.3M. Mirum Pharmaceuticals, Inc.'s net income of -$5.7M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Mirum Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 3.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mirum Pharmaceuticals, Inc. is 9.17x versus 2.40x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Insmed, Inc. has a net margin of -3.85% compared to Mirum Pharmaceuticals, Inc.'s net margin of -124.5%. Mirum Pharmaceuticals, Inc.'s return on equity of -8.84% beat Insmed, Inc.'s return on equity of -192.35%.

Mirum Pharmaceuticals, Inc. has a consensus price target of $122.36, signalling upside risk potential of 32.59%. On the other hand Insmed, Inc. has an analysts' consensus of $212.53 which suggests that it could grow by 42.32%. Given that Insmed, Inc. has higher upside potential than Mirum Pharmaceuticals, Inc., analysts believe Insmed, Inc. is more attractive than Mirum Pharmaceuticals, Inc..

Mirum Pharmaceuticals, Inc. has a beta of 0.492, which suggesting that the stock is 50.821% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.105, suggesting its more volatile than the S&P 500 by 10.538%.

Mirum Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mirum Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.

Mirum Pharmaceuticals, Inc. quarterly revenues are $148.9M, which are smaller than Insmed, Inc. quarterly revenues of $263.8M. Mirum Pharmaceuticals, Inc.'s net income of -$5.7M is higher than Insmed, Inc.'s net income of -$328.5M. Notably, Mirum Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mirum Pharmaceuticals, Inc. is 9.17x versus 48.98x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

XOMA Royalty Corp. has a net margin of -3.85% compared to Mirum Pharmaceuticals, Inc.'s net margin of 52.48%. Mirum Pharmaceuticals, Inc.'s return on equity of -8.84% beat XOMA Royalty Corp.'s return on equity of 17.31%.

Mirum Pharmaceuticals, Inc. has a consensus price target of $122.36, signalling upside risk potential of 32.59%. On the other hand XOMA Royalty Corp. has an analysts' consensus of $65.75 which suggests that it could grow by 157.54%. Given that XOMA Royalty Corp. has higher upside potential than Mirum Pharmaceuticals, Inc., analysts believe XOMA Royalty Corp. is more attractive than Mirum Pharmaceuticals, Inc..

Mirum Pharmaceuticals, Inc. has a beta of 0.492, which suggesting that the stock is 50.821% less volatile than S&P 500. In comparison XOMA Royalty Corp. has a beta of 0.855, suggesting its less volatile than the S&P 500 by 14.461%.

Mirum Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XOMA Royalty Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.54 per share. Mirum Pharmaceuticals, Inc. pays -- of its earnings as a dividend. XOMA Royalty Corp. pays out 39.59% of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Mirum Pharmaceuticals, Inc. quarterly revenues are $148.9M, which are larger than XOMA Royalty Corp. quarterly revenues of $9.4M. Mirum Pharmaceuticals, Inc.'s net income of -$5.7M is lower than XOMA Royalty Corp.'s net income of $10.3M. Notably, Mirum Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while XOMA Royalty Corp.'s PE ratio is 34.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mirum Pharmaceuticals, Inc. is 9.17x versus 8.88x for XOMA Royalty Corp.. Usually stocks with elevated PS ratios are considered overvalued.